OCUGEN INC OCGN 深 滬
已收盤 09-19 16:00:00 美东时间
1.34
-0.060
-4.29%
華盛通- 最 高1.42
- 今 開1.34
- 成交量 598.21万股
- 最 低 1.34
- 昨 收 1.40
- 總市值 4.18亿
- 52周最高 1.48
- 市盈率 靜 --
- 換手率 1.92%
- 52周最低 0.515
- 委 比 37.09%
- 總股本 3.12亿
- 歷史最高 18.77
- 量 比 0.76
- 振 幅 5.71%
- 歷史最低 0.17
- 每 手 1
- 風險率 0.49%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Ocugen Faces Merger Termination with Carisma Therapeutics
An update from Ocugen ( ($OCGN) ) is now available. On June 22, 2025, Ocugen an...
09-18 23:28
Ocugen Shares Are Trading Higher Monday: What's Going On?
Ocugen shares are trading higher Monday after the company announced a licensing agreement with Kwangdong Pharmaceutical for the exclusive Korean rights to OCU400.
09-16 04:29
Ocugen Strikes $7.5M Licensing Deal Giving Kwangdong Exclusive Korean Rights To Gene Therapy For Blindness
Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today executed a licensing agreement with Kwangdong Pharmaceutical, Co., Ltd.,
09-15 18:10
Ocugen Enters Subscription Agreement with Carisma Therapeutics
Ocugen ( ($OCGN) ) just unveiled an announcement. On August 29, 2025, Ocugen, I...
09-06 04:29
Why Alphabet Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket
Shares of Alphabet Inc. (NASDAQ:GOOGL) (NASDAQ:GOOG) rose sharply in pre-market...
09-03 17:23
Ocugen to Participate in H.C. Wainwright 27th Annual Global Investment Conference & Biotech on Tap 2025
Ocugen Inc., a biotech leader in gene therapies for blindness, announced that its CEO, Dr. Shankar Musunuri, will participate in fireside chats at the H.C. Wainwright Global Investment Conference and a panel at Biotech on Tap in Munich. The company’s executives will also hold one-on-one meetings to discuss their clinical strategies. The fireside chat will be webcast and archived for 90 days. Ocugen focuses on gene-agnostic modifier therapies for ...
09-02 11:02
Cassava Sciences GAAP EPS of -$0.92
Cassava Sciences press release (NASDAQ:SAVA): Q2 GAAP EPS of -$0.92. Cash and cash equivalents were $112.4 million, with no debt, as of June 30, 2025. This compares to cash and cash equivalents of $12...
08-14 19:41
Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU410ST—Modifier Gene Therapy for Stargardt Disease
Ocugen, Inc. announced that the European Medicines Agency (EMA) has accepted a single U.S.-based clinical trial for the submission of a Marketing Authorization Application (MAA) for its OCU410ST therapy targeting Stargardt disease. The trial, a pivotal confirmatory Phase 2/3 study, involves 51 participants and assesses the impact of a one-time subretinal injection of OCU410ST on reducing atrophic lesion size and improving vision. The EMA's positi...
08-13 10:27
